Adam Schechter Sells 8,705 Shares of Labcorp (NYSE:LH) Stock

Labcorp Holdings Inc. (NYSE:LH) CEO Adam Schechter sold 8,705 shares of the firm’s stock in a transaction dated Tuesday, March 3rd. The stock was sold at an average price of $279.96, for a total value of $2,437,051.80. Following the completion of the sale, the chief executive officer directly owned 80,773 shares of the company’s stock, valued at approximately $22,613,209.08. This represents a 9.73% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link.

Labcorp Price Performance

Shares of LH stock opened at $270.19 on Friday. Labcorp Holdings Inc. has a fifty-two week low of $209.38 and a fifty-two week high of $293.72. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.23 and a current ratio of 1.42. The firm has a market capitalization of $22.26 billion, a price-to-earnings ratio of 25.83, a PEG ratio of 1.88 and a beta of 1.01. The stock’s 50-day simple moving average is $271.00 and its 200-day simple moving average is $270.30.

Labcorp (NYSE:LH) last announced its quarterly earnings data on Tuesday, February 17th. The medical research company reported $4.07 EPS for the quarter, beating the consensus estimate of $3.95 by $0.12. The firm had revenue of $3.52 billion during the quarter, compared to analyst estimates of $3.56 billion. Labcorp had a net margin of 6.28% and a return on equity of 16.16%. Labcorp’s revenue was up 5.6% on a year-over-year basis. During the same period last year, the firm posted $3.45 EPS. Labcorp has set its FY 2026 guidance at 17.550-18.250 EPS. As a group, equities analysts forecast that Labcorp Holdings Inc. will post 16.01 earnings per share for the current fiscal year.

Labcorp Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 12th. Shareholders of record on Friday, February 27th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, February 27th. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.1%. Labcorp’s dividend payout ratio (DPR) is currently 27.53%.

Analyst Ratings Changes

A number of brokerages have recently weighed in on LH. Weiss Ratings raised shares of Labcorp from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. Piper Sandler raised their target price on Labcorp from $270.00 to $300.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 24th. Robert W. Baird lifted their price target on Labcorp from $313.00 to $326.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 18th. Wall Street Zen upgraded Labcorp from a “hold” rating to a “buy” rating in a research note on Friday, January 23rd. Finally, Morgan Stanley reissued an “overweight” rating on shares of Labcorp in a report on Tuesday, February 17th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat, Labcorp presently has a consensus rating of “Moderate Buy” and an average price target of $304.82.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of the company. Hsbc Holdings PLC grew its position in shares of Labcorp by 33.8% during the 4th quarter. Hsbc Holdings PLC now owns 189,502 shares of the medical research company’s stock valued at $47,608,000 after acquiring an additional 47,850 shares during the period. SHP Wealth Management purchased a new position in Labcorp during the fourth quarter worth approximately $40,000. Caitong International Asset Management Co. Ltd grew its holdings in Labcorp by 2,979.2% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 739 shares of the medical research company’s stock valued at $185,000 after purchasing an additional 715 shares during the period. CFO Capital Management LLC acquired a new stake in Labcorp in the fourth quarter valued at approximately $563,000. Finally, MidFirst Bank purchased a new stake in shares of Labcorp in the fourth quarter valued at approximately $150,000. Institutional investors and hedge funds own 95.94% of the company’s stock.

Labcorp Company Profile

Laboratory Corporation of America Holdings, commonly known as Labcorp (NYSE: LH), is a global life sciences company that provides comprehensive clinical laboratory and drug development services. The company operates a broad network of laboratories, patient service centers and specialty testing sites to deliver diagnostic information and testing solutions that support patient care, clinical decision-making and population health initiatives.

Labcorp’s core businesses encompass clinical laboratory testing and pharmaceutical development services.